Avant Diagnostics, Inc.’s ("AVANT" or AVDX) technology intends to realize patient-focused precision medicine in cancer treatment. Both biopharma companies developing drugs and oncologists treating patients find that Avant’s Theralink® assay has the potential to enable clear decision making for an individual patient’s cancer treatment using predictive biomarkers.
Providing Physicians with a Unique and Powerful Treatment Decision Information Resource
Avant will provide personalized medicine data through its Theralink® assays, initially for breast cancer, to assist the treating physician in a data-driven process for treatment decision support and potentially enable new predictive biomarker-based patient selection. Avant is the leading developer of phosphoproteomic technologies for measuring the activation state of key drug targets and signaling pathways, with applications across multiple cancer types, including breast, non-small cell lung, colorectal and pancreatic. Theralink® was developed to empower physicians with potentially actionable information to help them make time-sensitive treatment decisions for their patients. Theralink® was designed to provide new predictive biomarkers through the direct measurement of drug target activation mapping making Theralink® instrumental in the development of companion diagnostics for molecular-targeted therapies. The information gathered through measurement of developed biomarkers has the potential to help physicians make molecularly rationalized treatment decisions that could improve treatment outcomes and reduce side effects by foregoing ineffective therapy.
Science Backed by Strong Leadership
Meet the team that is the driving force behind our success.